The Failure Of Biosimilars In The US: ‘Headline’ News
Executive Summary
A Washington Post article on price hikes for Abbvie’s Humira highlights patent ‘thickets’ and anti-biosimilar strategies. But the lack of understanding of the basic concepts of the biosimilar system are a much bigger warning sign about the viability of the pathway.
You may also be interested in...
AAM's Francer Talks Quality, Pricing And Biosimilars
Association for Accessible Medicines interim CEO and general counsel Jeff Francer, in an interview with Generics Bulletin sister publication Scrip, discusses the industry body’s continued efforts to ensure that generics and biosimilars are not disadvantaged in the US by the brand name industry's commercial tactics or legal/regulatory moves, and outlines the 'enormous progress' made by generic firms on quality.
AAM’s Francer On Tackling Tactics That Hurt Market Access For Gx, Biosimilars
Association for Accessible Medicines interim CEO and general counsel Jeff Francer, in an interview with Scrip, discusses the industry body’s continued efforts to ensure that generics and biosimilars are not disadvantaged in the US by the brand name industry's commercial tactics or legal/regulatory moves, and outlines the 'enormous progress' made by generic firms on quality.
Biosimilars In US Drug Pricing Debate: Second Chance – Or Maybe Last Chance
Current drug pricing legislative effort offers the prospect of a substantial update to 2010 biosimilar law – substantial at least in the list of statutory changes, if not in the potential near term impact on the marketplace.